You are here: Industry Insights > Astellas

News List

FiercePharmaAsia—Astellas job cuts, GSK vet’s $260M Chinese startup, Sun's Zytiga knockoff fiercepharma
May 28, 2018
Astellas' new CEO is pushing for a round of layoffs in RD and sales and marketing that will cost 600 jobs. GlaxoSmit
Astellas begins major restructure, as 600 jobs slashed pharmafile
May 25, 2018
Astellas, under the direction of new CEO, Kenji Yasukawa, has unveiled a major new restructure, ahead of a difficult looking year financially in 2019.
Astellas to pay Aquinox $25M upfront for regional rights to phase 3 inflammatory pain drug fiercebiotech
May 16, 2018
Astellas is paying Aquinox Pharmaceuticals $25 million upfront for regional rights to rosiptor.
Astellas files experimental AML therapy pharmatimes
April 27, 2018
Astellas has filed its experimental Acute Myeloid Leukaemia (AML) therapy gilteritinib with US regulators, seeking approval for its use to treat FLT3 mutation-positive (FLT3mut+) relapsed or refractory forms of the blood cancer.
Astellas sells certain U.S. research facilities to Gilead biospectrumasia
April 23, 2018
The facilities transfer is part of the wind-down process of the Agensys research operations.
Actinium, Astellas Form Research Partnership contractpharma
March 30, 2018
Actinium Pharmaceuticals has entered into a research and option agreement with Astellas to develop Actinium-225 Radio-Conjugates (ARCs) using its Actinium Warhead Enabling (AWE) Platform Technology.
USFDA grants priority to XTANDI's sNDA biospectrumasia
March 21, 2018
When approved, the sNDA would expand the indication of XTANDI to include men with non-metastatic Castration-Resistant Prostate Cancer
Astellas Reports Financial Results for the First Nine Months of FY2017 biospace
February 01, 2018
Astellas today announced the financial results for the first nine months of fiscal year 2017 ending March 31, 2018 (“FY2017”).
Cytokinetics Announces Progress Against Vision 2020 biospace
January 04, 2018
Cytokinetics, Inc. (NASDAQ: CYTK) announced today the progress associated with its 2020 vision
Astellas buys DMD drug in $450M mitochondrial takeover fiercebiotech
December 04, 2017
Astellas has acquired its partner Mitobridge in a deal worth up to $450 million. The takeover gives Astellas full control of a phase 1 Duchenne muscular dystrophy (DMD) drug in return for $225 million upfront and the same again down the line.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page